Redsense Medical AB has decided not to renew its agreement with OTC Markets Group after the current term, which ends on December 31, 2024. Redsense Medical began trading on the OTCQX platform on September 29, 2023 under the symbol “RDSNF”.
“While our time on the OTCQX platform has provided valuable insights, we have chosen to refocus our efforts toward key priotities that will better support our growth. Our primary goal is to accelarate profitability, and we believe the most effective use of our resources will be to drive sales growth and enhance communication with our strong and engaged shareholder base, which has steadily grown since our listing in 2015”, says Sebastien Bollue, CEO of Redsense Medical AB.
Contact information
For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.
